BACKGROUND: Clinical features associated with Gram-negative bacterial isolates with extended-spectrum beta-lactamase (ESBL)- and AmpC-mediated resistance identified in Canadian hospitals is largely unknown. The objective of the present study was to determine the demographics, risk factors and outcomes of patients with ESBL- or AmpC-mediated resistant organisms in Canadian hospitals. METHODS: Patients with clinical cultures of Escherichia coli or Klebsiella species were matched with patients with a similar organism but susceptible to third-generation cephalosporins. Molecular identification of the AmpC or ESBL was determined using a combination of polymerase chain reaction and sequence analysis. Univariate and multivariate logistic regression analysis was performed to identify variables associated with becoming a case. RESULTS: Eight Canadian hospitals identified 106 cases (ESBL/AmpC) and 106 controls. All risk factors identified in the univariate analysis as a predictor of being an ESBL/AmpC cases at the 0.20 P-value were included in the multivariate analysis. No significant differences in outcomes were observed (unfavourable responses 17% versus 15% and mortality rates 13% versus 7%, P not significant). Multivariate logistic regression found an association of becoming an ESBL/AmpC case with: previous admission to a nursing home (OR 8.28, P=0.01) or acute care facility (OR 1.96, P=0.03), length of stay before infection (OR 3.05, P=0.004), and previous use of first-generation cephalosporins (OR 2.38, P=0.02) or third-generation cephalosporins (OR 4.52, P=0.01). Appropriate antibiotics were more likely to be given to controls (27.0% versus 13.3%, P=0.05) and number of days to appropriate antibiotics was longer for cases (median 2.8 days versus 1.2 days, P=0.05). CONCLUSION: The importance of patient medical history, present admission and antibiotic use should be considered for all E coli or Klebsiella species patients pending susceptibility testing results.
BACKGROUND: Clinical features associated with Gram-negative bacterial isolates with extended-spectrum beta-lactamase (ESBL)- and AmpC-mediated resistance identified in Canadian hospitals is largely unknown. The objective of the present study was to determine the demographics, risk factors and outcomes of patients with ESBL- or AmpC-mediated resistant organisms in Canadian hospitals. METHODS:Patients with clinical cultures of Escherichia coli or Klebsiella species were matched with patients with a similar organism but susceptible to third-generation cephalosporins. Molecular identification of the AmpC or ESBL was determined using a combination of polymerase chain reaction and sequence analysis. Univariate and multivariate logistic regression analysis was performed to identify variables associated with becoming a case. RESULTS: Eight Canadian hospitals identified 106 cases (ESBL/AmpC) and 106 controls. All risk factors identified in the univariate analysis as a predictor of being an ESBL/AmpC cases at the 0.20 P-value were included in the multivariate analysis. No significant differences in outcomes were observed (unfavourable responses 17% versus 15% and mortality rates 13% versus 7%, P not significant). Multivariate logistic regression found an association of becoming an ESBL/AmpC case with: previous admission to a nursing home (OR 8.28, P=0.01) or acute care facility (OR 1.96, P=0.03), length of stay before infection (OR 3.05, P=0.004), and previous use of first-generation cephalosporins (OR 2.38, P=0.02) or third-generation cephalosporins (OR 4.52, P=0.01). Appropriate antibiotics were more likely to be given to controls (27.0% versus 13.3%, P=0.05) and number of days to appropriate antibiotics was longer for cases (median 2.8 days versus 1.2 days, P=0.05). CONCLUSION: The importance of patient medical history, present admission and antibiotic use should be considered for all E coli or Klebsiella species patients pending susceptibility testing results.
Authors: Michael R Mulvey; Elizabeth Bryce; David A Boyd; Marianna Ofner-Agostini; Allison M Land; Andrew E Simor; Shirley Paton Journal: Antimicrob Agents Chemother Date: 2005-01 Impact factor: 5.191
Authors: D A Schiappa; M K Hayden; M G Matushek; F N Hashemi; J Sullivan; K Y Smith; D Miyashiro; J P Quinn; R A Weinstein; G M Trenholme Journal: J Infect Dis Date: 1996-09 Impact factor: 5.226
Authors: Jan M Bell; John D Turnidge; Ana C Gales; Michael A Pfaller; Ronald N Jones Journal: Diagn Microbiol Infect Dis Date: 2002-03 Impact factor: 2.803
Authors: John M Quale; David Landman; Patricia A Bradford; Melissa Visalli; Jayshree Ravishankar; Carlos Flores; David Mayorga; Kalyani Vangala; Adedeyo Adedeji Journal: Clin Infect Dis Date: 2002-09-10 Impact factor: 9.079
Authors: C Peña; C Gudiol; L Calatayud; F Tubau; M A Domínguez; M Pujol; J Ariza; F Gudiol Journal: J Hosp Infect Date: 2008-01-15 Impact factor: 3.926
Authors: Geoffrey Taylor; Denise Gravel; Lynora Saxinger; Kathryn Bush; Kimberley Simmonds; Anne Matlow; Joanne Embree; Nicole Le Saux; Lynn Johnston; Kathryn N Suh; John Embil; Elizabeth Henderson; Michael John; Virginia Roth; Alice Wong Journal: Can J Infect Dis Med Microbiol Date: 2015 Mar-Apr Impact factor: 2.471